In full COVID-19 emergency, most scientific studies have focused their research on adult patients. New drugs, vaccines and transmissibility factors were only analysed in the case of adult patients and children and adolescents were given little consideration. As it is...
The WHO has initiated a comprehensive gap analysis of the most needed medicines for children in view of its upcoming review of the Essential Medicines List for children (EMLc). To support the WHO review of the Essential Medicines List for children, the Global...
In occasion of the fourteenth edition of the Rare Disease Day, promoted by EURORDIS, that will be held on February 28th, TEDDY Network has become a friend and is supporting this great initiative again this year! The main objective of Rare Disease Day is to raise...
The EJP RD is organising an online webinar to provide the potential applicants to the Joint Transnational Call 2021 on “Social Sciences and Humanities Research to Improve Health Care Implementation and Everyday Life of People Living with a Rare Disease” details on the...
On 6 January 2021, The European Commission has closed the Public Consultation for the inception impact assessment on the revision of the Orphan and Paediatric Regulation. The aim of this initiative was to explore the need for adequate measures to overcome the lack of...
In December 2020 both Pfizer- BioNTech’s and Moderna’s COVID-19 vaccines were approved by the Food and Drugs Administration (FDA), while the Pfizer Vaccine was approved by the European Medicines Agency (EMA) in December 2020 and Moderna’s vaccine in January 2021. In...
We are happy to announce that even this year and with an ongoing pandemic, the youths of KIDS Bari have kicked off their activities[ML1] ! On November 27, KIDS BARI went back to work to promote the involvement of young persons and patients in the research and clinical...
The European Joint Programme on Rare Diseases (EJP RD) has launched the EJP RD Joint Transnational Call (JTC) 2021 and will fund multilateral research projects on rare diseases under the EJP-COFUND action. EJP RD has successfully implemented two Joint Transnational...
During the COVID-19 pandemic, the European Medicines Agency (EMA) is implementing exceptional measures to maximise the transparency of its regulatory activities on treatments and vaccines for COVID-19 that are approved or are under evaluation. EMA is achieving this by...
The European Medicines Agency (EMA) organized a forum on 15 December 2020 to address the following objectives: - inform on implementation of the HMA-EMA Big Data Task Force; priority recommendations; - understand stakeholders’ perspectives; - discuss opportunities for...